PDF herunterladen
Thromb Haemost 1984; 51(03): 321-325
DOI: 10.1055/s-0038-1661092
Original Article
Schattauer GmbH Stuttgart

Metabolism of Sodium Pentosan Polysulphate in Man – Catabolism of Iodinated Derivatives

I R MacGregor
1   The Scottish National Blood Transfusion Service Headquarters Unit Laboratory, Edinburgh, Scotland, U.K.
,
J Dawes
2   The MRC/SNBTS Blood Components Assay Group, Edinburgh, Scotland, U.K.
,
L Paton
3   The S-E Scotland Blood Transfusion Service, Royal Infirmary, Edinburgh, Scotland, U.K.
,
D S Pepper
1   The Scottish National Blood Transfusion Service Headquarters Unit Laboratory, Edinburgh, Scotland, U.K.
,
C V Prowse
3   The S-E Scotland Blood Transfusion Service, Royal Infirmary, Edinburgh, Scotland, U.K.
,
M Smith
4   The Department of Medical Physics and Medical Engineering, Royal Infirmary, Edinburgh, Scotland, U.K.
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 15. November 1983

Accepted 08. März 1984

Publikationsdatum:
19. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

An iodinated derivative of the heparin analogue SP54 has been prepared and used in conjunction with unlabelled SP54 to study the catabolism and organ distribution of this potential antithrombotic agent in healthy human volunteers. As observed previously with 125I-heparin, we found that the 125I-SP54 was rapidly cleared from the circulation, returning later in a desulphated form. Organ distribution studies with 123I-SP54 suggested that the liver and spleen were major sites of desulphation. Gel filtration and Polybrene binding showed the presence of sulphated macromolecular SP54 and desulphated macromolecular and depolymerised SP54 in post-injection urines. No depolymerised material was present in plasma suggesting depolymerisation occurs in the kidney.

Keywords

Heparin analogue - SP54 - Metabolism - Iodinated derivatives - Organ distribution
 

  • References

  • 1 Thomas DP, Lane DA, Michalski R, Johnson EA, Kakkar VV. A heparin analogue with specific action on antithrombin III. Lancet 1977; 1: 120-122
    PubMedGoogle Scholar
  • 2 Lane DA, Michalski R, Van Ross ME, Kakkar VV. Comparison of heparin and a semisynthetic heparin analogue, A 73025. Br J Haematol 1977; 37: 239-245
    CrossrefPubMedGoogle Scholar
  • 3 Thomas DP, Barrowcliffe TW, Johnson EA, Stocks J, Dawes J, Pepper DS. A heparin analogue that releases endogenous heparan sulphate. Thromb Haemostas 1979; 42: 418 (Abstr.)
    PubMedGoogle Scholar
  • 4 Soria C, Soria J, Rychewaert JJ, Holmer E, Caen JP. Anticoagulant activities of a pentosane polysulphate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 1980; 19: 455-463
    CrossrefPubMedGoogle Scholar
  • 5 Ryde M, Eriksson H, Tangen O. Studies on the different mechanisms by which heparin and polysulphated xylans (PZ 68) inhibit blood coagulation in man. Thromb Res 1981; 23: 435-445
    CrossrefPubMedGoogle Scholar
  • 6 Vinazzer H, Haas S, Stemberger A. Influence on the clotting mechanism of sodium pentosan polysulphate (SP54) in comparison to commercial beef lung sodium heparin. Thromb Res 1980; 20: 57-68
    CrossrefPubMedGoogle Scholar
  • 7 Bergqvist D, Nilsson IM. A sulphated polysaccharide - the effects in vivo and in vitro on the haemostatic system in healthy volunteers. Thromb Res 1981; 23: 309-315
    CrossrefPubMedGoogle Scholar
  • 8 Fischer AM, Merton RE, Marsh NA, Williams S, Gaffney PJ, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate and heparin II: Effects of subcutaneous injection. Thromb Haemostas 1982; 47: 109-113
    PubMedGoogle Scholar
  • 9 Bergqvist D, Efsing HO, Hallbook T, Lindblad B. Prevention of postoperative thromboembolic complications: a prospective comparison between Dextran 70, Dihydroergotamin heparin and a sulphated polysaccharide. Acta Chir Scand 1980; 146: 559-568
    PubMedGoogle Scholar
  • 10 Bergqvist D, Ljunger H. A comparative study of Dextran 70 and a sulphated polysaccharide in the prevention of postoperative thromboembolic complications. Br J Surg 1981; 68: 449-451
    CrossrefPubMedGoogle Scholar
  • 11 Dawes J, Pepper DS. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860
    CrossrefPubMedGoogle Scholar
  • 12 Greenwood FC, Hunter WM, Glover JS. The preparation of 131I- labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114-123
    CrossrefPubMedGoogle Scholar
  • 13 Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Comm 1976; 69: 570-577
    CrossrefPubMedGoogle Scholar
  • 14 Cash JD, Gader AM A, Mulder JL, Cort JH. Structure activity relations in the fibrinolytic response to vasopressin in man. Clin Sci Molec Med 1978; 54: 403-409
    PubMedGoogle Scholar
  • 15 Losito R, Barlow G, Lemieux E. 3H-heparin and antithrombin III in the isolated liver perfusion. Thromb Res 1977; 10: 83-89
    CrossrefPubMedGoogle Scholar
  • 16 de Swaart CA M, Sixma JJ, Andersson L-O, Holmer E, Verschoor L, Nijmeyer A. Kinetics in normal humans of anticoagulant activity, radioactivity and lipolytic activity after intravenous administration of (35S) heparin and (35S) heparin fractions. Scand J Haematol 1980; 25 Suppl (Suppl. 36) 50-63
    PubMedGoogle Scholar
  • 17 Kitani T, Nagarajan SC, Shanberge JN. Effect of protamine on heparin-antithrombin III complexes - in vivo studies. Thromb Res 1980; 17: 375-382
    CrossrefPubMedGoogle Scholar
  • 18 Effeney JD, Case SA, Graziano C, Blaisdel FW. Distribution and clearance of radioactive heparin. Surg Forum 1979; 30: 198-199
    PubMedGoogle Scholar
  • 19 Bethell GS, Ayers JS, Hancock WS, Hearn MT W. A novel method of activation of cross-linked agarose with 1,1-carbonyldiimidazole which gives a matrix for affinity chromatography devoid of additional charged groups. J Biol Chem 1979; 254: 2572-2574
    PubMedGoogle Scholar
  • 20 Mahadoo J, Hiebert L, Jaques LB. Vascular sequestration of heparin. Thromb Res 1977; 12: 79-90
    PubMedGoogle Scholar
  • 21 Farooqui AA. Sulfatases, sulfate esters and their metabolic disorders. Clin Chim Acta 1980; 100: 285-299
    CrossrefPubMedGoogle Scholar
  • 22 McAllister BM, Demis DJ. Heparin metabolism: isolation and characterisation of uroheparin. Nature 1966; 212: 293-294
    CrossrefPubMedGoogle Scholar